¿ Antex Biologics Inc., of Gaithersburg, Md., restructured its four-year alliance with SmithKline Beecham plc, of London. SKB received a 12 percent equity position through the exercising of an existing option and warrants to purchase an additional 10 percent of Antex common stock. The new agreement provides Antex with the opportunity to continue antigen discovery research with SKB as well as develop human vaccines. The agreement gives SKB exclusive worldwide rights to certain Antex human vaccines in exchange for undisclosed milestone payments, royalties and payment of certain other expenses.
¿ Cantab Pharmaceuticals plc, of Cambridge, UK, reported positive results from the final stage of a Phase I trial with DISC HSV vaccine for genital herpes, which is being developed with Glaxo Wellcome plc, of London. A Phase II trial is now under way to define the optimum dosing regimen for the suppression of recurrent genital herpes.
¿ Cell Genesys Inc., of Foster City, Calif., will provide its proprietary adenoviral and adeno-associated viral gene delivery technologies to Pharmacia & Upjohn, of Bridgewater, N.J. P&U will use the technology to evaluate certain applications of gene therapy in animal health. The two companies will consider a further business relationship based on the results of the studies performed. Financial terms were not disclosed.
¿ CollaGenex Pharmaceuticals Inc., of Newtown, Pa., signed a co-promotion agreement with Merck & Co. Inc., of Whitehouse Station, N.J., for Vioxx (rofecoxib) to the dental market. Vioxx is a non-steroidal anti-inflammatory drug that was approved in May. CollaGenex will use its 125-person dental pharmaceutical sales force to promote Vioxx. Other terms were not disclosed. CollaGenex's stock (NASDAQ:CGPI) gained 46 percent Thursday to $22.375.
¿ Hyseq Inc., of Sunnyvale, Calif., launched a web site, GeneSolutions.com, that provides researchers access to results from more than 12 million DNA samples analyzed by Hyseq. The company believes it has found almost all of the 150,000 human genes that Hyseq scientists estimated to exist in a presentation made in 1993.
¿ Immtech International Inc., of Evanston, Ill., said it will enter a Phase I trial in the first quarter of 2000 with DAP-092 for the treatment of Cryptosporidium and Giardia parasitical infections. DAP-092 is designed to treat severe diarrhea and wasting syndromes caused by the parasites.
¿ Inflazyme Pharmaceuticals Ltd., of Vancouver, British Columbia, selected IPL 423,323 as its lead compound from its IPL423 series as a potential new treatment of psoriasis and organ transplant rejection. The compound has demonstrated in animal models that it is as effective as cyclosporin, the current standard treatment for inhibition of organ transplant rejection.
¿ Medarex Inc., of Annandale, N.J., signed a five-year antibody development agreement with Amgen Inc., of Thousand Oaks, Calif. Medarex will uses its proprietary HuMAb-Mouse technology to generate fully human monoclonal antibodies to multiple targets for Amgen. Amgen will be responsible for product development, manufacturing and marketing of any products and Medarex will receive research and development payments from Amgen as well as possible additional fees and milestone payments plus royalties on future product sales.
¿ Myriad Genetics Inc., of Salt Lake City, said it discovered a gene involved in the inherited susceptibility to insulin-dependent diabetes. This discovery may offer help to researchers in development of new ways to treat insulin-dependent diabetes, the company said. It was discovered through an internal program based on analysis of families with insulin-dependent diabetes. Myriad estimated the gene may account for 10 percent to 15 percent of insulin-dependent diabetes. Myriad's stock (NASDAQ:MYGN) gained 38 percent Thursday to close at $19.375.
¿ NeoTherapeutics Inc., of Irvine, Calif., is conducting a Phase II trial to study the effects of Neotrofin (AIT-082, leteprinim potassium) directly in the brain. The study at the University of California at Irvine, involves a limited number of patients with mild to moderate Alzheimer's disease. Phase I studies and a recently completed Phase IIa trial showed Neotrofin can be orally administered and provides positive effects on memory and behavioral functions.
¿ NeuroVir Therapeutics Inc., of Vancouver, British Columbia, said an intravenous delivery of its G207 tumor-killing herpes simplex virus vector was effective in the treatment of human prostate tumors in mice. The results were published in the September issue of Human Gene Therapy.
¿ Ribi ImmunoChem Research Inc., of Hamilton, Mont., said its shareholders approved its merger with Corixa Corp. Corixa's stockholders are expected to consider the merger today. (See BioWorld Today, June 11, 1999, p. 1.)
¿ StressGen Biotechnologies Corp., of Victoria, British Columbia, completed its Phase I trial of HspE7 (SGN-00101). The randomized, placebo-controlled, double-blind study included 24 patients. The company will proceed to a Phase II trial in anal dysphasia, also known as anal intraepithelial neoplasia, a condition caused by the human papillomavirus. HspE7 is a recombinant fusion product composed of heat shock protein 65 from M. bovis BCG and the protein E7 from HPV16.